3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 24 points (-0.2%) at 14,029 as of Friday, March 1, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,249 issues advancing vs. 1,609 declining with 131 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Medivation ( MDVN), down 6.6%, ResMed ( RMD), down 2.0% and Sanofi ( SNY), down 0.6%. Top gainers within the sector include Celgene Corporation ( CELG), up 1.4%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Express Scripts ( ESRX), up 0.6%, Stryker Corporation ( SYK), up 0.8% and Amgen ( AMGN), up 0.5%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Vertex Pharmaceuticals is down $0.75 (-1.6%) to $46.07 on average volume Thus far, 788,143 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $45.52-$46.58 after having opened the day at $46.55 as compared to the previous trading day's close of $46.82.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $10.2 billion and is part of the drugs industry. Shares are up 12.1% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants